Lifecore Biomedical, Inc. (LFCR)
After hours:
| Previous Close | 5.77 |
| Open | 5.85 |
| Bid | 5.80 x 100 |
| Ask | 5.89 x 200 |
| Day's Range | 5.58 - 5.91 |
| 52 Week Range | 4.50 - 11.46 |
| Volume | |
| Avg. Volume | 200,398 |
| Market Cap | 179.31M |
| Beta (5Y Monthly) | 0.98 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Lifecore Biomedical Completes Incremental Liquidity Initiatives
Recent Initiatives Provide Approximately $8 Million of Non-Dilutive, Incremental Liquidity through Various Amendments with LendersCHASKA, Minn., May 16, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), announced certain incremental liquidity measures and housekeeping matters related to divested businesses through a series of 8-K filings over the past week. James G. Hal
- GlobeNewswire
Lifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delayed Quarterly Report
CHASKA, Minn., April 19, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (the “Company”) announced today that, on April 15, 2024, the Company received a notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of the Company’s delay in filing its Quarterly Report on Form 10-Q for the fiscal quarter ended February 25, 2024 (the “Q3 Form 10-Q”) and its continued delay in filing its Quarter
- GlobeNewswire
Lifecore Biomedical Provides Business Update Outlining Fiscal 2024 Outlook and Year-to-date Progress
Year-to-date Results Consistent with Prior Expectations; Experiencing Fiscal Second Half Lift Provides Fiscal 2024 Full Year Guidance Commercial Momentum Continues within Development Portfolio Capacity Expansion Projects Progressing CHASKA, Minn., April 01, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today provided a business update, including certain select preli
